Get the Stockscreener App
2.62
5.22%
0.13
After Hours:
2.60
-0.02
-0.76%
2 Seventy Bio Inc stock is traded at $2.62, with a volume of 193.74K.
It is up +5.22% in the last 24 hours and down -9.34% over the past month.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
See More
Previous Close:
$2.49
Open:
$2.52
24h Volume:
193.74K
Relative Volume:
0.60
Market Cap:
$135.68M
Revenue:
$44.12M
Net Income/Loss:
$-156.25M
P/E Ratio:
-0.8534
EPS:
-3.07
Net Cash Flow:
$-154.61M
1W Performance:
+4.38%
1M Performance:
-9.34%
6M Performance:
-46.75%
1Y Performance:
-34.66%
1-Day Range:
$2.47
$2.705
1-Week Range:
$2.41
$2.76
52-Week Range:
$2.345
$6.40
2 Seventy Bio Inc Stock (TSVT) Company Profile
Name
2 Seventy Bio Inc
Sector
Industry
Phone
339-499-9300
Address
60 BINNEY STREET, CAMBRIDGE
Compare TSVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSVT
2 Seventy Bio Inc
|
2.62 | 135.68M | 44.12M | -156.25M | -154.61M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-24 | Downgrade | Goldman | Neutral → Sell |
| Jan-31-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-31-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-30-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| May-02-22 | Initiated | Goldman | Buy |
| Feb-10-22 | Initiated | SVB Leerink | Outperform |
| Jan-06-22 | Initiated | Cowen | Outperform |
| Nov-09-21 | Initiated | Canaccord Genuity | Buy |
| Nov-08-21 | Initiated | Morgan Stanley | Overweight |
| Nov-08-21 | Initiated | Wedbush | Outperform |
View All
2 Seventy Bio Inc Stock (TSVT) Latest News
Layoff Tracker: Biogen to Cut Undisclosed Number of Research Employees - BioSpace
Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World
Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report - Simply Wall St
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress - Business Wire
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results - GlobeNewswire
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference - Business Wire
2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Exchange Traded Concepts LLC - Defense World
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) - Yahoo Finance
Dimensional Fund Advisors LP Sells 24,371 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
BMS and 2seventy bio Axe Trial for Ide-Cel in Newly Diagnosed Multiple Myeloma - CGTLive™
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance - Business Wire
Seven Eight Capital LP Makes New $197,000 Investment in Beyond, Inc. (NYSE:BYON) - Defense World
Q&A: Athens legends Five Eight and the makers of their new documentary film, "Weirdo" - Online Athens
Four killed, dozens injured in Alabama mass shooting - Daily Sun
Seven Eight Capital LP Sells 536 Shares of Dell Technologies Inc. (NYSE:DELL) - Defense World
Four dead, 17 others shot in Birmingham mass shooting - WJLA
Five Below, Inc. (NASDAQ:FIVE) Stake Raised by Teca Partners LP - Defense World
Four killed, over 20 injured in Birmingham, Alabama shooting - Thaiger World
At least four dead and dozens injured in shootout with multiple assailants in the United States - Top Buzz Times
Four people dead and dozens injured in US mass shooting horror - Express
Analyst bullish on Tectonic's TX45 ahead of full trial results presentation at AHA - Investing.com India
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 - GlobeNewswire
Hedge fund Two Sigma in settlement talks with US SEC, WSJ reports - XM
2 Seventy Bio Inc Stock (TSVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2 Seventy Bio Inc Stock (TSVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Snow Jessica | See Remarks |
Jan 03 '25 |
Sale |
2.94 |
1,000 |
2,936 |
152,479 |
| Snow Jessica | See Remarks |
Jan 07 '25 |
Sale |
2.64 |
186 |
491 |
147,179 |
| Leschly Nick | Director |
Jan 03 '25 |
Sale |
2.94 |
85,978 |
252,423 |
1,234,498 |
| Leschly Nick | Director |
Jan 06 '25 |
Sale |
2.78 |
892 |
2,478 |
1,233,606 |
| Eatwell Victoria | Chief Financial Officer |
Jan 03 '25 |
Sale |
2.94 |
1,013 |
2,974 |
339,076 |
| Eatwell Victoria | Chief Financial Officer |
Jan 06 '25 |
Sale |
2.78 |
97 |
270 |
338,979 |
| Baird William D III | President and CEO |
Jan 03 '25 |
Sale |
2.94 |
31,718 |
93,121 |
862,889 |
| Baird William D III | President and CEO |
Jan 06 '25 |
Sale |
2.78 |
763 |
2,120 |
862,126 |
| Snow Jessica | See Remarks |
Dec 13 '24 |
Sale |
3.23 |
2,287 |
7,393 |
153,479 |
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):